Contrive Datum Insights has published "Next Generation Complement Therapeutics Market Size, Share & Industry Analysis, By Complement pathway target (C5 Inhibitors, C3 Inhibitors, Factor B/D Inhibitors, MASP-2 Inhibitors, Other Targets), Therapeutic modality (Monoclonal Antibodies, Small Molecule Inhibitors, Peptide Inhibitors, Oligonucleotide/RNA-Targeted Therapies), Indication (Paroxysmal Nocturnal Hemoglobinuria, Atypical Hemolytic Uremic Syndrome, Generalized Myasthenia Gravis, Geographic Atrophy, Other Indications), Route of administration (Intravenous, Subcutaneous, Oral), End user (Hospitals, Specialty Clinics, Home Care/Home Infusion), and Regional Forecast, 2026-2034". The study sizes the global next generation complement therapeutics market at USD 9.4 billion in 2025 and projects growth from USD 10.85 billion in 2026 to USD 34.4 billion by 2034, a compound annual growth rate of 15.5% across the forecast period.
Next generation complement therapeutics are biologic and small-molecule medicines that block specific proteins in the complement cascade, a part of the immune system that can cause tissue damage when it becomes chronically overactive. They are prescribed by hematologists, nephrologists, neurologists and ophthalmologists to treat rare and chronic conditions where uncontrolled complement activity destroys blood cells, kidney tissue, neuromuscular function or retinal tissue. Buyers are hospitals, specialty pharmacies and infusion or home-care providers that dispense and administer these therapies under ongoing physician supervision.
Regulatory approvals expanding across indications
Regulatory approvals expanding across indications is the largest single contributor to the market's growth over the forecast period, and the study rates its impact high. Against a market growing at 15.5% a year, the complement pathway target lines exposed to it move fastest: C3 Inhibitors compounds at 19.7%, taking its share of revenue from 17.98% to 25% and its value from USD 1.69 billion to USD 8.6 billion.
The study also runs a bull case: bull case assumes faster label expansion into geographic atrophy and generalized myasthenia gravis alongside quicker payer adoption of oral and subcutaneous formulations. That path ends 2034 at USD 39.8 billion, above the USD 34.4 billion base case.
The downside is specific. Bear case assumes slower reimbursement approval in ex-US markets and prescribing caution following a safety signal that delays uptake of newer pathway targets, and 2034 revenue lands at USD 28.5 billion. C5 Inhibitors is the drag, 62.02% of the 2025 base compounding at 12.8% while the market runs at 15.5%.
Where the Competition Actually Sits
Competition in the global next generation complement therapeutics market runs along the complement pathway target axis, not the regional one. C5 Inhibitors holds 62.02% of 2025 revenue at USD 5.83 billion and remains the largest line through 2034 at 50%, making it the position hardest for a challenger to take. C3 Inhibitors, growing at 19.7%, is where share actually changes hands. A supplier established in one is not thereby established in the other, so a field of this size persists in a market of USD 9.4 billion.
Further Report Findings
| Segment | Led 2025 by | Share & value | Fastest-growing |
|---|---|---|---|
| Therapeutic modality | Monoclonal Antibodies | 57.98% · USD 5.45 billion | Small Molecule Inhibitors 19.9% |
| Indication | Paroxysmal Nocturnal Hemoglobinuria | 35% · USD 3.29 billion | Geographic Atrophy 20.8% |
| Route of administration | Intravenous | 67.98% · USD 6.39 billion | Oral 26.5% |
| End user | Hospitals | 52.02% · USD 4.89 billion | Home Care/Home Infusion 21.7% |
- Regionally, the lead sits with North America: 60.6% of 2025 global revenue, USD 5.7 billion rising to USD 18.92 billion in 2034.
- Europe takes a rising share of global revenue over the forecast period, from 22.3% in 2025 to 23% in 2034, with revenue growing from USD 2.1 billion to USD 7.91 billion.
- At 2.3% of 2025 revenue and 2.5% by 2034, Middle East and Africa is the smallest region throughout.
- By complement pathway target, the largest line in 2025 was C5 Inhibitors, at 62.02% of revenue and USD 5.83 billion.
- C3 Inhibitors is projected to grow at 19.7% over the forecast period, the fastest of any complement pathway target line.
- The United States is the largest single country market at USD 5.2 billion in 2025, 55.3% of global revenue.
Every year from 2020 to 2034 is reported, with revenue and growth for each line across five axes: by complement pathway target, and by therapeutic modality, indication, route of administration and end user. The headline total carries bear, base and bull cases at USD 28.5 billion and USD 39.8 billion by 2034. The study also breaks out all five regions to country level, sets out the competitive landscape, and documents the method behind every estimate. Available as a PDF, with a free sample on request.